OSL Stock Overview
A medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OncoSil Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.005 |
| 52 Week High | AU$0.013 |
| 52 Week Low | AU$0.004 |
| Beta | 0.42 |
| 1 Month Change | 11.11% |
| 3 Month Change | -33.33% |
| 1 Year Change | -58.33% |
| 3 Year Change | -91.53% |
| 5 Year Change | -90.57% |
| Change since IPO | -94.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| OSL | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -9.1% | -2.9% | -1.7% |
| 1Y | -58.3% | -11.2% | 7.0% |
Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned -11.2% over the past year.
Return vs Market: OSL underperformed the Australian Market which returned 7% over the past year.
Price Volatility
| OSL volatility | |
|---|---|
| OSL Average Weekly Movement | 25.8% |
| Life Sciences Industry Average Movement | 10.3% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in AU Market | 16.4% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: OSL's share price has been volatile over the past 3 months.
Volatility Over Time: OSL's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Nigel Lange | www.oncosil.com.au |
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited Fundamentals Summary
| OSL fundamental statistics | |
|---|---|
| Market cap | AU$16.66m |
| Earnings (TTM) | -AU$11.71m |
| Revenue (TTM) | AU$1.30m |
12.8x
P/S Ratio-1.4x
P/E RatioIs OSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSL income statement (TTM) | |
|---|---|
| Revenue | AU$1.30m |
| Cost of Revenue | AU$1.87m |
| Gross Profit | -AU$573.73k |
| Other Expenses | AU$11.13m |
| Earnings | -AU$11.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0035 |
| Gross Margin | -44.18% |
| Net Profit Margin | -901.58% |
| Debt/Equity Ratio | 0% |
How did OSL perform over the long term?
See historical performance and comparison